Stock Comparison

CRMD vs LLY

CorMedix Inc vs Eli Lilly and Co

The Verdict

CRMD takes this one.

Winner

CRMD

CorMedix Inc

8.9

out of 10

Hidden Gem

LLY

Eli Lilly and Co

0.5

out of 10

Distressed

Head-to-Head

$646M

Market Cap

$965.0B

3.6

P/E Ratio

52.6

45.3%

Profit Margin

N/A

50.4%

Return on Equity

N/A

0.4

Debt-to-Equity

N/A

Moderate

Overall Risk

Moderate

8.9

DVR Score

0.5

The Deep Dive

CRMD8.9/10

CorMedix Inc. exhibits significantly de-risked commercialization with exceptional Q1 2026 results, reporting $127.4 million in revenue and $38.6 million in net income, handily beating revenue estimates. The company substantially raised its FY2026 guidance to $325M-$345M revenue and $115M-$135M adjusted EBITDA, demonstrating strong market adoption of DefenCath and effective integration of the Melin...

Full CRMD Analysis

LLY0.5/10

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...

Full LLY Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.